Continuum Advisory’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.14M | Sell |
3,254
-4
| -0.1% | -$1.43K | 0.11% | 175 |
|
|
2025
Q4 | $1.07M | Sell |
3,258
-240
| -7% | -$76.1K | 0.11% | 180 |
|
|
2025
Q3 | $987K | Sell |
3,498
-264
| -7% | -$76.6K | 0.1% | 178 |
|
|
2025
Q2 | $1.05M | Sell |
3,762
-1,873
| -33% | -$531K | 0.13% | 159 |
|
|
2025
Q1 | $1.76M | Buy |
5,635
+481
| +9% | +$142K | 0.23% | 96 |
|
|
2024
Q4 | $1.34M | Buy |
5,154
+35
| +0.7% | +$10.4K | 0.17% | 121 |
|
|
2024
Q3 | $1.51M | Buy |
5,119
+620
| +14% | +$203K | 0.19% | 111 |
|
|
2024
Q2 | $1.41M | Buy |
4,499
+13
| +0.3% | +$3.82K | 0.2% | 111 |
|
|
2024
Q1 | $1.4M | Sell |
4,486
-836
| -16% | -$245K | 0.21% | 111 |
|
|
2023
Q4 | $1.53M | Buy |
5,322
+987
| +23% | +$269K | 0.22% | 119 |
|
|
2023
Q3 | $1.16M | Buy |
4,335
+1,340
| +45% | +$334K | 0.19% | 144 |
|
|
2023
Q2 | $665K | Sell |
2,995
-114
| -4% | -$26.5K | 0.11% | 229 |
|
|
2023
Q1 | $752K | Buy |
3,109
+101
| +3% | +$24.8K | 0.13% | 192 |
|
|
2022
Q4 | $790K | Buy |
3,008
+253
| +9% | +$67.8K | 0.14% | 175 |
|
|
2022
Q3 | $621K | Sell |
2,755
-42
| -2% | -$10.2K | 0.11% | 201 |
|
|
2022
Q2 | $681K | Buy |
2,797
+205
| +8% | +$50.2K | 0.12% | 205 |
|
|
2022
Q1 | $604K | Buy |
2,592
+913
| +54% | +$210K | 0.11% | 215 |
|
|
2021
Q4 | $378K | Sell |
1,679
-591
| -26% | -$125K | 0.09% | 214 |
|
|
2021
Q3 | $483K | Buy |
2,270
+427
| +23% | +$98.3K | 0.13% | 167 |
|
|
2021
Q2 | $449K | Buy |
+1,843
| New | +$453K | 0.14% | 160 |
|
|
2020
Q3 | – | Sell |
-857
| Closed | -$219K | – | 151 |
|
|
2020
Q2 | $219K | Buy |
+857
| New | +$196K | 0.14% | 127 |
|
|
2019
Q1 | – | Sell |
-1,394
| Closed | -$271K | – | 130 |
|
|
2018
Q4 | $271K | Sell |
1,394
-227
| -14% | -$44.3K | 0.2% | 120 |
|
|
2018
Q3 | $335K | Sell |
1,621
-897
| -36% | -$177K | 0.22% | 103 |
|
|
2018
Q2 | $465K | Sell |
2,518
-80
| -3% | -$14.2K | 0.34% | 71 |
|
|
2018
Q1 | $443K | Sell |
2,598
-1,387
| -35% | -$255K | 0.37% | 68 |
|
|
2017
Q4 | $693K | Buy |
3,985
+111
| +3% | +$19.6K | 0.53% | 39 |
|
|
2017
Q3 | $722K | Sell |
3,874
-66
| -2% | -$11.7K | 0.63% | 39 |
|
|
2017
Q2 | $679K | Buy |
3,940
+737
| +23% | +$120K | 0.67% | 38 |
|
|
2017
Q1 | $526K | Buy |
+3,203
| New | +$532K | 0.63% | 44 |
|
Other funds holding AMGN
VCM
VPM
Continuum Advisory's AMGN Position: Q1 2026 in Review
Continuum Advisory reduced its Amgen (AMGN) stake by 0.12% in Q1 2026, selling an estimated $1.43K and leaving 3,254 shares worth $1.14M. The position accounts for 0.11% of the portfolio, ranked #175.
Continuum Advisory first reported a position in AMGN in Q1 2017 and has held it in 29 quarters since. The position peaked at $1.76M in Q1 2025. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Continuum Advisory held 3,254 shares of Amgen worth $1.14M as of Q1 2026.
- Continuum Advisory sold 4 Amgen shares in Q1 2026, an estimated $1.43K.
- Amgen made up 0.11% of Continuum Advisory's portfolio in Q1 2026, its #175 holding.
- Continuum Advisory first reported a position in Amgen in Q1 2017 and has held it in 29 quarters since.
- Continuum Advisory's Amgen position peaked at $1.76M in Q1 2025.
- 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.